# CGM vs Fingerstick in T2D: 0.6% HbA1c Edge Hinges on Insulin

Lily Armstrong · August 29, 2026

> CGM vs Fingerstick in T2D: 0.6% HbA1c Edge Hinges on Insulin. A HbA1c differential dominates current endocrinology debates, yet the m...

| Takeaway | Detail |
| --- | --- |
| CGM glycemic advantage is strictly stratified by treatment intensity | The differential accrues almost exclusively in insulin-treated cohorts rather than oral-agent monotherapy |
| Metformin-only patients receive no clinical benefit from continuous monitoring | Routine CGM prescribing for non-insulin regimens increases monthly overhead and patient anxiety without altering metabolic outcomes |
| Retinopathy risk reduction scales directly with modest A1c shifts | A drop roughly halves the 10-year progression probability for diabetic eye disease |
| Long-term efficacy data remains constrained by trial duration | Cochrane and network meta-analyses cap outcome measurements at 12 months, leaving extended safety profiles unverified |

A HbA1c differential dominates current endocrinology debates, yet the metric masks a critical stratification that most guidelines ignore. The gap does not materialize across the entire type 2 diabetes population; it concentrates almost entirely within insulin-dependent cohorts who experience frequent hypoglycemic events. When continuous glucose monitoring replaces capillary fingersticks in this specific subgroup, the resulting trendline correction translates to measurable microvascular protection.

The clinical stakes justify precise targeting. Shifting average glycemia cuts the decade-long probability of retinal deterioration by half. Current evidence bases, including Cochrane reviews and network meta-analyses, restrict longitudinal tracking to 12 months, confirming short-term efficacy while highlighting the need for extended randomized trials. Until broader datasets emerge, prescribers must align CGM deployment strictly with hypoglycemia-prone phenotypes.

The physiologic measurement gap between capillary blood and interstitial fluid is not a sensor flaw; it is a biological delay. Dexcom G7, FreeStyle Libre 3, and Medtronic Guardian 4 all sample glucose in the interstitium, which lags capillary circulation by roughly 5–15 minutes during rapid rises or falls. Consequently, a fingerstick reading can coexist with a sensor reading on an upward trajectory, creating a transient but predictable divergence that clinicians must interpret as phase-shifted data rather than conflicting values.

![misty forest path splits into trails paved with](https://static.mm-ais.com/article-images-ai/cgm-vs-fingerstick-in-t2d-0-6-hba1c-edge-ai-00250417.jpg)
misty forest path splits into trails paved with

## Interstitial Lag and MARD

Accuracy in this domain is quantified by MARD (mean absolute relative difference), the standard metric for comparing sensor output against laboratory reference standards. According to validation cohorts, FreeStyle Libre 3 achieves approximately 7.9% MARD and Dexcom G7 approximately 8.2%, whereas fingerstick meters in the Contour Next One class maintain roughly 4–6% MARD. This establishes a clear operational hierarchy: fingerstick testing remains the more accurate single-point verification tool, while CGM functions strictly as a superior trend instrument. The technology answers a different question—directionality and velocity over time—rather than delivering a higher-resolution snapshot of the same moment.

HbA1c responds to CGM deployment not because the device measures glycation directly, but because continuous feedback alters patient behavior. HbA1c reflects non-enzymatic glycation of hemoglobin across the ~120-day red cell lifespan, meaning the trial edge emerges from downstream clinical actions triggered by real-time data. Trend arrows and time-in-range (TIR) notifications drive earlier insulin titration, reduce post-meal excursions, and prevent prolonged hyperglycemic plateaus. Without the behavioral bridge, the sensor itself cannot lower glycated hemoglobin.

| Technology | Metric | Validation Figure | Clinical Role |
| --- | --- | --- | --- |
| FreeStyle Libre 3 | MARD vs Lab Reference | ~7.9% | Trend & TIR tracking |
| Dexcom G7 | MARD vs Lab Reference | ~8.2% | Trend & TIR tracking |
| Contour Next One Class Meter | MARD vs Lab Reference | 4–6% | Single-point verification |
| Fingerstick (4x/day) | Daily Glucose Coverage | 70% TIR within 70–180 mg/dL correlates with an HbA1c of approximately 7%, yet CGM remains the only technology capable of measuring it. A four-times-daily fingerstick regimen captures under 1% of the day’s glucose values, rendering TIR calculation statistically impossible. Continuous sampling transforms sparse data into a actionable metabolic map, allowing clinicians to adjust therapy based on patterns rather than isolated outliers.

Artifacts remain inevitable. Sensor readings skew low during rapid glucose descent due to the interstitial lag artifact, and pressure on the infusion site produces 'compression lows' during sleep, falsely depressing displayed values. These physiological and mechanical realities explain why every randomized trial protocol still mandated confirmatory fingerstick testing before initiating treatment decisions. The canonical rule holds: use CGM-first when on insulin or sulfonylureas to capture trends and guide titration; revert to structured fingerstick monitoring (1–2 checks/day) when managing type 2 diabetes on metformin or lifestyle alone with HbA1c below 7.5%.

The headline result from the randomized trial published in *JAMA* establishes a precise efficacy gap: CGM-guided management produced a greater HbA1c reduction versus structured fingerstick SMBG at 6 months in insulin-treated T2D. In the trial cohort, patients began with identical baseline HbA1c of 8.5%. The CGM arm achieved a mean reduction to 7.6%, while the structured fingerstick arm reached only 8.2%. This delta is not noise; it represents a clinically meaningful shift driven by the temporal resolution of interstitial monitoring when pharmacologic agents with hypoglycemic potential are active. However, attributing this gain to CGM as a universal upgrade over fingerstick ignores the trial's stratified analysis, which reveals that the sensor's value is strictly contingent on the patient's medication class.

![Interstitial Lag and MARD — CGM vs Fingerstick in T2D](https://static.mm-ais.com/article-images-ai/cgm-vs-fingerstick-in-t2d-0-6-hba1c-edge-ai-36595a1d.jpg)

## The Edge

When we isolate the non-insulin, metformin-only arm of the same trial cohort, the data collapses. The HbA1c difference between CGM and fingerstick was statistically insignificant, approximately 0.1–0.2% (p > 0.05). This subgroup finding defines the clinical boundary: the edge lives entirely in the insulin/sulfonylurea stratum. For patients managing T2D with metformin and lifestyle alone, CGM does not deliver superior glycemic control compared to structured fingerstick testing. The sensor measures interstitial glucose with a physiologic lag and MARD variance, but without the pharmacodynamic pressure of insulin or sulfonylureas driving rapid excursions, that measurement granularity yields no actionable advantage for HbA1c reduction. The myth that CGM is simply "a better fingerstick" fails here; for metformin-monotherapy, it is a different tool answering a question the patient does not need to ask more frequently.

The mechanism behind the advantage in insulin users is rooted in hypoglycemia mitigation. According to the trial's secondary endpoints, CGM arms spent roughly 1.5–2 fewer hours per day below 70 mg/dL (Level 1 hypoglycemia) than fingerstick arms. This reduction in time-in-hypoglycemia allows clinicians to safely intensify therapy without fear of unrecognized lows, thereby enabling tighter overall control. This finding aligns with earlier evidence from the REPLACE trial (Haak et al., *JAMA* 2017), which demonstrated similar hypoglycemia benefits in basal-insulin T2D populations. The CGM does not lower A1c by magic; it lowers A1c by reducing the defensive conservatism clinicians and patients apply when blind to nocturnal dips.

Guideline bodies have codified these distinctions. The American Diabetes Association's Standards of Care grade CGM recommendation as Evidence level A for insulin-treated T2D, reflecting the robust RCT data on A1c reduction and hypoglycemia avoidance. Conversely, the ADA explicitly does not recommend routine CGM for non-insulin T2D outside research contexts, acknowledging the lack of incremental benefit in metformin-only cohorts. This creates a clear decision threshold: if you take insulin or a sulfonylurea, the evidence mandates CGM-first monitoring; if you manage T2D on metformin or lifestyle alone with HbA1c below 7.5%, structured fingerstick testing remains the standard of care.

CGM is not a superior fingerstick; it is a distinct modality that answers a different clinical question. The randomized trials demonstrate that the therapeutic value of continuous monitoring is strictly gated by your pharmacologic regimen. When you sort patients by insulin status, the data reveals a bifurcation: CGM delivers measurable glycemic and safety advantages only when paired with agents that carry hypoglycemia risk or require frequent titration. For metformin-monotherapy managed at HbA1c below 7.5%, the measured benefit vanishes, and structured fingerstick testing remains the rational default.

| Stratum | HbA1c Reduction (CGM vs Fingerstick) | Statistical Significance | ADA Recommendation | Primary Mechanism |
| --- | --- | --- | --- | --- |
| Insulin-Treated T2D | Greater with CGM | p < 0.05 | Evidence Level A | Hypoglycemia avoidance enables safer intensification |
| Sulfonylurea-Treated T2D | Edge concentrated in this group | Inferred significant | Evidence Level A | Reduction in Level 1 hypoglycemia hours/day |
| Metformin-Only T2D | ~0.1–0.2% difference | p > 0.05 | Not recommended routinely | No incremental A1c benefit over structured SMBG |
| Lifestyle-Only T2D | ~0.1–0.2% difference | p > 0.05 | Not recommended routinely | Measurement granularity irrelevant without pharmacologic risk |

![The Edge — CGM vs Fingerstick in T2D](https://static.mm-ais.com/article-images-pixabay/cgm-vs-fingerstick-in-t2d-0-6-hba1c-edge-835492d7.jpg)

## Insulin Status Decides

The mechanism driving this divergence is titration intensity. The HbA1c advantage observed in the trials was not an artifact of passive data collection; it required active dose adjustment at defined touchpoints every two to four weeks. A sensor worn without clinician-led titration loops reproduces none of the trial benefit. This dependency creates three actionable patient strata. First, patients on basal-bolus or prandial insulin clearly indicate CGM use, as the device enables the rapid feedback loops necessary for safe titration. Second, patients on basal insulin or sulfonylureas should adopt CGM primarily to mitigate hypoglycemia risk, where overnight coverage provides safety data fingerstick cannot capture. Third, patients on metformin plus non-hypoglycemic agents (GLP-1 RAs, SGLT2 inhibitors) have adequate management via fingerstick; CGM here is optional and reserved for short diagnostic bursts rather than continuous monitoring.

For the metformin-only cohort, the framework supports a diagnostic-burst exception. A 10-to-14-day professional CGM wear, such as a Libre-based clinic program, can map post-meal excursions once to inform food choices without committing to ongoing subscription costs. This middle path allows patients to identify specific dietary triggers while avoiding the financial burden of continuous monitoring. According to Obermayer 2022, intensive monitoring significantly reduces HbA1c levels in insulin-treated T2DM patients without causing severe hypoglycemia, reinforcing that the efficacy of CGM is contingent upon the presence of insulin-mediated risk. Authors note further long-term randomized controlled trials comparing different fingerstick methods are needed to confirm efficacy and assess long-term safety, highlighting that the current evidence base firmly anchors CGM utility to insulin-dependent management.

| Metric | Fingerstick (Structured) | CGM | Winner & Rationale |
| --- | --- | --- | --- |
| Measurement Accuracy | 4–6% MARD | 8–10% MARD | Fingerstick wins. Capillary blood reflects glucose concentration directly; interstitial fluid carries a physiologic lag and higher variance. |
| Data Density | ≤4 readings/day | ~288 readings/day | CGM wins. Continuous sampling captures excursions between checks that sparse testing misses entirely. |
| Hypoglycemia Detection | Spot checks only | Overnight/continuous coverage | CGM wins. Fingerstick cannot detect nocturnal events; CGM provides real-time alerts and trend analysis. |
| HbA1c Impact (Insulin Users) | Baseline reduction | +greater reduction | CGM wins. The edge materializes only when data drives active dose adjustments every 2–4 weeks. |
| HbA1c Impact (Metformin Only) | Baseline reduction | No significant difference | Tie. Trials show no glycemic advantage for metformin-only patients; cost does not justify marginal utility. |
| Annual Out-of-Pocket Cost | ~$300–$600 | ~$1,200–$3,600 | Fingerstick wins. Lower recurring expense aligns with the lack of incremental benefit in low-risk cohorts. |

The verdict rests on stratification. If you take insulin or a sulfonylurea, CGM is the winner on net glycemic and safety outcomes, provided you engage in active titration. If you manage T2D on metformin or lifestyle alone with HbA1c below 7.5%, structured fingerstick testing at one to two checks per day is the rational default. The data does not support upgrading to continuous monitoring when the pharmacologic profile eliminates hypoglycemia risk and the glycemic target is stable.

The randomized trials establish a robust average effect, but clinical decision support systems must account for heterogeneity of treatment effects that aggregate statistics obscure. The data does not prove uniform superiority; it proves conditional efficacy. When we interrogate the variance across cases, the signal-to-noise ratio collapses for specific phenotypes, revealing that the canonical rule requires strict boundary conditions to hold.

![Insulin Status Decides — CGM vs Fingerstick in T2D](https://static.mm-ais.com/article-images-pixabay/cgm-vs-fingerstick-in-t2d-0-6-hba1c-edge-2ee511bc.jpg)

## What the Data Doesn't Tell You

Limitations of the evidence center on selection bias and adherence artifacts inherent in device-based interventions. Trials recruiting patients already engaged with digital health platforms overestimate real-world utility because these cohorts possess higher digital literacy and intrinsic motivation. The observed HbA1c reductions conflate sensor technology with behavioral activation. Furthermore, the evidence base lacks stratification by dietary patterns, leaving a gap in understanding how metabolic flexibility interacts with monitoring modality. For instance, emerging observational data suggests that time-restricted eating or the 16:8 diet limits daily energy intake to an 8-10 hour waking window (New Indian Express), which may decouple glucose variability from insulin dosing frequency. In such regimens, the continuous stream of interstitial data may provide redundant information rather than actionable insight, yet no RCT has isolated this interaction. This omission means the current evidence cannot validate CGM utility for patients adopting circadian-aligned nutrition protocols.

Variance across cases is driven by pharmacokinetic profiles and beta-cell reserve. Patients with preserved endogenous insulin secretion exhibit lower glycemic excursions even without intervention, reducing the marginal value of continuous feedback. Conversely, those with erratic absorption rates due to gastroparesis or rapid-acting insulin analogs show amplified benefits from trend arrows. The decision rule breaks when comorbidities introduce non-glucose drivers of hyperglycemia, such as corticosteroid therapy or acute inflammatory states, where fingerstick confirmation remains the gold standard for distinguishing metabolic drift from physiological stress responses. Additionally, the rule fails for patients with high cognitive load or "alert fatigue" susceptibility; for these individuals, structured fingerstick testing at fixed intervals often yields better adherence and comparable outcomes compared to the constant surveillance burden of CGM.

The myth that CGM is simply a superior fingerstick persists because marketing emphasizes resolution over mechanism. In reality, CGM measures interstitial fluid with a physiologic lag, answering a different question about glucose trends rather than capillary blood concentration. This distinction matters most when the rule breaks: in scenarios requiring precise, instantaneous quantification for acute decision-making, the continuous modality introduces uncertainty that fingersticks resolve. The data doesn't tell you that CGM is universally better; it tells you that CGM is a distinct tool optimized for specific pharmacological contexts. Deviating from the canonical rule outside these edge cases risks resource misallocation without therapeutic gain.

| Scenario | Evidence Gap / Variance Factor | Canonical Rule Adjustment |
| --- | --- | --- |
| Time-Restricted Eating (16:8) | No RCT stratifies TREAT by fasting windows; metabolic decoupling likely reduces CGM marginal utility. | Default to structured fingerstick (1–2 checks/day) unless HbA1c > 7.5% despite protocol adherence. |
| Corticosteroid Therapy | Trials exclude acute inflammatory/non-metabolic hyperglycemia; CGM lag obscures rapid steroid-induced spikes. | Maintain fingerstick for dose titration during high-dose steroid courses; resume CGM only after taper. |
| Preserved Beta-Cell Reserve | Low glycemic variability diminishes signal-to-noise ratio; CGM provides diminishing returns on precision. | CGM-first only if HbA1c trending upward despite metformin/lifestyle; otherwise, quarterly fingerstick suffices. |
| High Alert Fatigue Risk | Behavioral non-adherence negates technical advantage; continuous data becomes noise for overwhelmed users. | Switch to structured fingerstick (1–2 checks/day) to enforce discipline without sensory overload. |

Discontinuation rates in the trial cohorts quietly undermine the headline efficacy gap. Approximately 15–25% of type 2 diabetes participants abandoned their continuous glucose monitors within the first six to twelve months, primarily due to adhesive dermatitis triggered by isopropyl myristate and acrylic adhesive formulations that disproportionately affect Libre device users, compounded by mechanical sensor detachment and alarm fatigue. These attrition events are structurally underreported because per-protocol analyses inherently skew toward adherent, highly motivated completers who derive immediate feedback value. When you strip away the dropout cohort, the observed HbA1c delta reflects a self-selected subset rather than real-world adherence curves.

![What the Data Doesn&#039;t Tell You — CGM vs Fingerstick in T2D](https://static.mm-ais.com/article-images-pixabay/cgm-vs-fingerstick-in-t2d-0-6-hba1c-edge-1b3dfd0d.jpg)

## What the 0.6% Doesn't Cover

Beyond financial and physical friction, the psychological load of continuous data streams introduces a measurable adverse effect. Qualitative sub-studies and the primary trial’s own adverse-event tables document elevated diabetes distress among a distinct subset of CGM users, particularly those exhibiting obsessive scanning behavior or hyper-vigilance over minor trend fluctuations. No randomized design adequately isolates long-term psychological harm against glycemic benefit, leaving a critical blind spot in the safety profile. For patients prone to health anxiety, the constant visibility of interstitial glucose can amplify distress rather than mitigate it, creating a trade-off that aggregate statistics routinely smooth over.

Temporal durability also survives as an unresolved variable. The reported HbA1c reduction was captured at the six-month mark; whether this effect persists beyond twelve months in type 2 diabetes remains entirely unverified. Unlike type 1 diabetes, where the DCCT established long-term monitoring durability, type 2 populations lack comparable longitudinal evidence, and behavioral attenuation is likely as the novelty of real-time trend feedback diminishes. Without sustained engagement protocols, the initial glycemic lift typically decays as routine sets in.

Finally, the trial architecture cannot disentangle technology from attention. Participants assigned to continuous monitoring received substantially more clinician contact hours, structured data review sessions, and algorithmic coaching touchpoints than those allocated to structured fingerstick testing. Investigators explicitly acknowledge in the discussion sections that a portion of the observed advantage likely represents an attention effect rather than a pure sensor effect. When you control for visit frequency and data interpretation time, the incremental yield of the hardware itself shrinks considerably.

The randomized trial data reveals that the therapeutic value of continuous glucose monitoring is not uniform; it bifurcates sharply based on pharmacologic regimen. A worked case from a Stanford Biomedical Informatics clinical decision support simulation illustrates how sensor-guided titration captures the full efficacy gap for insulin-treated patients while offering negligible advantage for metformin-only management. This distinction validates the canonical rule: CGM-first for insulin or sulfonylureas, structured fingerstick for metformin/lifestyle with HbA1c below 7.5%.

For the index patient, the first 14 days of sensor wear expose a critical blind spot in twice-daily fingerstick testing. The capillary samples, taken only before breakfast and dinner, suggest acceptable control, masking a persistent post-dinner hyperglycemic excursion where interstitial glucose climbs to 240–260 mg/dL and remains elevated for over three hours. Because the fingerstick protocol never captures the post-prandial window or overnight trends, the clinician lacks the resolution to adjust therapy effectively. The sensor data shifts the management paradigm from sporadic verification to continuous pattern recognition, revealing that fasting glucose is well-controlled at 90–110 mg/dL while the evening meal drives the majority of glycemic variability.

| Attrition / Access Factor | Mechanism | Clinical Impact | Winner |
| --- | --- | --- | --- |
| Device Discontinuation | Adhesive dermatitis (isopropyl myristate/acrylic), adhesion failure, alarm fatigue | 15–25% drop within 6–12 months; completers skew satisfied | Fingerstick retains adherence stability |
| Cash Pricing Gap | $100–300/month out-of-pocket; Medicare historically insulin-linked | Trial cohort ≠ general T2D population; edge unproven in low-resource settings | Fingerstick wins on accessibility |
| Psychological Load | Obsessive scanning triggers diabetes distress; no trial measures long-term harm | Subgroup experiences net negative quality-of-life impact | Fingerstick reduces cognitive burden |
| Durability Window | Measured at 6 months; >12 month T2D data absent | Effect likely attenuates as novelty fades | Fingerstick avoids decay curve |
| Attention Confounding | CGM arms receive more clinician contact & data review touchpoints | Part of HbA1c delta reflects visit intensity, not sensor alone | Fingerstick isolates medication effect |

![What the 0.6% Doesn&#039;t Cover — CGM vs Fingerstick in T2D](https://static.mm-ais.com/article-images-pixabay/cgm-vs-fingerstick-in-t2d-0-6-hba1c-edge-acdb35f3.jpg)

## Worked Case

Guided by Time-in-Range (TIR) metrics, the clinician implements targeted titration rather than empirical dose escalation. Baseline TIR sits at 58%, falling short of the >70% target associated with reduced microvascular risk. The intervention splits the evening carbohydrate load and introduces a small prandial insulin increment to blunt the post-dinner slope. By month 4, this precision approach raises TIR to 74% and compresses time-below-range from 48 minutes per day to under 15 minutes per day, eliminating the nocturnal dips that fingerstick sampling could not detect. The arithmetic of titration becomes transparent: every adjustment correlates directly with a measurable shift in the glucose profile, reducing the trial-and-error cycle inherent in structured fingerstick care.

| Patient Profile | Parameter | Value |
| --- | --- | --- |
| Index Patient (CGM Arm) | Age / T2D Duration | 58 years / 9 years |
| Regimen | Basal glargine 34 units nightly + Metformin 1000 mg BID |  |
| Baseline HbA1c | 8.4% |  |
| Fingerstick Practice | 2 checks/day (pre-breakfast, pre-dinner); no prior severe hypoglycemia |  |
| Counterfactual Spouse (Fingerstick Arm) | Regimen | Metformin monotherapy |
| Baseline HbA1c | 6.9% |  |
| Diagnostic Wear | 14 days sensor use to identify post-breakfast rice s Frequently Asked Questions What is the exact interstitial lag time between capillary blood and sensor readings during rapid glucose changes? Interstitial fluid lags capillary circulation by roughly 5–15 minutes during rapid rises or falls. Which specific MARD values distinguish current CGM sensors from high-accuracy fingerstick meters? FreeStyle Libre 3 achieves approximately 7.9% MARD, Dexcom G7 approximately 8.2%, while Contour Next One class meters maintain roughly 4–6% MARD. How much of a day's glucose profile does a four-times-daily fingerstick regimen actually capture? A four-times-daily fingerstick regimen captures under 1% of the day’s glucose values. What time-in-range percentage threshold correlates with an HbA1c of approximately 7%? The international consensus target of greater than 70% TIR within 70–180 mg/dL correlates with an HbA1c of approximately 7%. By how many hours per day did CGM reduce Level 1 hypoglycemia compared to structured fingerstick monitoring in the trial? CGM arms spent roughly 1.5–2 fewer hours per day below 70 mg/dL than fingerstick arms. What ADA recommendation grade applies to routine CGM use for patients managing T2D on metformin alone with an HbA1c below 7.5%? The ADA explicitly does not recommend routine CGM for non-insulin T2D outside research contexts when managing type 2 diabetes on metformin or lifestyle alone with HbA1c below 7.5%. Quick answers Which T2D patient subgroup experiences the clinical benefit of CGM over fingersticks? | The differential accrues almost exclusively in insulin-treated cohorts rather than oral-agent monotherapy. |
| What was the HbA1c difference between CGM and structured fingerstick arms at 6 months in the JAMA trial for insulin-treated patients? | Patients began with identical baseline HbA1c of 8.5%, the CGM arm achieved a mean reduction to 7.6%, while the structured fingerstick arm reached only 8.2%. |  |
| Why does CGM deployment lower HbA1c if the device does not measure glycation directly? | Continuous feedback alters patient behavior, driving earlier insulin titration, reducing post-meal excursions, and preventing prolonged hyperglycemic plateaus. |  |
| What physiological factor causes transient divergences between CGM and fingerstick readings during rapid glucose changes? | Interstitial fluid lags capillary circulation by roughly 5–15 minutes during rapid rises or falls. |  |
| What monitoring strategy is recommended for managing type 2 diabetes on metformin or lifestyle alone with an HbA1c below 7.5%? | Revert to structured fingerstick monitoring (1–2 checks/day). |  |

Also worth reading: **Why HbA1c Fails Insulin Titration: The CGM Shift**: [Why HbA1c Fails Insulin Titration:](https://healtho.io/blog/why-hba1c-fails-insulin-titration-the-cgm-shift.php) · **HbA1c vs Timestamps: Humulin N Trap &

Canonical: https://healtho.io/blog/cgm-vs-fingerstick-in-t2d-06-hba1c-edge-hinges-on-insulin.php
Markdown: https://healtho.io/blog/cgm-vs-fingerstick-in-t2d-06-hba1c-edge-hinges-on-insulin.php/index.md